Board members

Carl-Fredrik Lindner
Carl-Fredrik Lindner
Chairman of the Board

Lindner, born in 1976, with a Master of Science from KTH Royal Institute of Technology, Stockholm, Sweden. Carl-Fredrik is the responsible Investment Manager at Lionpeak AB, Stockholm, Sweden. He has a background in Corporate Finance and worked with a Venture Capital fund, investing in Life Science. Lindner has been the Chairman and a member of Annexin’s Board since 2017.

Shareholding in the Company: 0 shares

Johan Frostegård
Johan Frostegård
Member of the board

Professor Frostegård, born in 1959, is Head of Department of Immunology and Chronic Disease at the Institute of Environmental Medicine, Karolinska Institute, Stockholm. Professor Frostegård leads a group of 10 – 15 research workers. He is a specialist in Internal Medicine and Rheumatology and is Senior Consultant at the Institute of Emergency Healthcare at Karolinska University Hospital, Huddinge. Professor Frostegård is the inventor of around 20 patent applications, several granted and around 140 original scientific publications and several books. Frostegård has been a member of Annexin Pharmaceuticals board since 2016.

Shareholding in the Company: 1 873 296 indirectly, via Frostskog AB and Medirista AB (which own 1 369 296 and 504 000 shares in Annexin respectively).

 

Gisela Sitbon
Gisela Sitbon
Member of the board

Sitbon, born in 1958, holds a Doctorate in Medical Sciences from Karolinska Institutet, Stockholm, Sweden and twenty-five years’ experience in the life science industry, over ten years in senior positions. Sitbon is member of the board at a number of companies, among others she is the chairman at Nanologica AB. Sitbon has been a member of Annexin’s board since 2017.

Shareholding in the Company: 12 000

Lena Torlegård
Lena Torlegård
Member of the board

Torlegård, born 1963, has a M.Sc. in Business and Economics, and works as a communication advisor at Springtime-Intellecta AB. She is specialized in financial and corporate communication with several customers in the field of life science. Torlegård is a member of the board of several companies and of Annexin since 2018.

Shareholding in the Company: 77 273